Saffron, Passionflower, Valerian and Sage for Mental Health

Psychiatric Clinics of North America

Volumn 36, Issue 1, 2013, Pages 85-91

  Modabbernia, Amirhossein ^a   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ADHD; Anxiety; Crocus sativus; Depression; Insomnia; Passiflora incarnata; Salvia officinalis; Valeriana officinalis

Indexed keywords

CLONIDINE; CROCUS SATIVUS EXTRACT; FLUOXETINE; IMIPRAMINE; OXAZEPAM; PASSIFLORA INCARNATA EXTRACT; PLACEBO; SALVIA OFFICINALIS EXTRACT; VALERIAN; PLANT EXTRACT;

ADD ON THERAPY; ALZHEIMER DISEASE; ANXIETY DISORDER; CONVULSION; CROCUS SATIVUS; DEMENTIA; DEPRESSION; DRUG MEGADOSE; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FALL RISK; HALLUCINATION; HEART VENTRICLE TACHYCARDIA; HERBAL MEDICINE; HUMAN; MEAN ARTERIAL PRESSURE; OBSESSIVE COMPULSIVE DISORDER; OPIATE ADDICTION; PASSIFLORA INCARNATA; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; QT PROLONGATION; REVIEW; SALVIA OFFICINALIS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYSTOLIC BLOOD PRESSURE; TONIC CLONIC SEIZURE; VALERIANA OFFICINALIS; WITHDRAWAL SYNDROME; CROCUS; MENTAL DISORDERS; PASSIFLORA; PHYTOTHERAPY;

CROCUS; HUMANS; MENTAL DISORDERS; PASSIFLORA; PHYTOTHERAPY; PLANT EXTRACTS; SALVIA OFFICINALIS; VALERIAN;

EID: 84875607240     PISSN: 0193953X     EISSN: 15583147     Source Type: Journal    
DOI: 10.1016/j.psc.2012.12.007     Document Type: Review

References (37)

1. Akhondzadeh S. Herbal medicine in the treatment of psychiatric and neurological disorders. Low cost approaches to promote physical and mental health: theory research and practice 2007, 119-138. Springer, New York. L. L'Abate (Ed.).
2. Kamalipour M., Jamshidi A.H., Akhondzadeh S. Antidepressant effect of Crocus sativus: an evidence based review. Journal of Medicinal Plants 2010, 9(Suppl 6):35-38.
3. Akhondzadeh Basti A., Moshiri E., Noorbala A.A., et al. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31(2):439-442. 10.1016/j.pnpbp.2006.11.010.
4. Akhondzadeh S., Fallah-Pour H., Afkham K., et al. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med 2004, 4:12. 10.1186/1472-6882-4-12.
5. Akhondzadeh S., Tahmacebi-Pour N., Noorbala A.A., et al. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res 2005, 19(2):148-151. 10.1002/ptr.1647.
6. Moshiri E., Basti A.A., Noorbala A.A., et al. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: a double-blind, randomized and placebo-controlled trial. Phytomedicine 2006, 13(9-10):607-611. 10.1016/j.phymed.2006.08.006.
7. Noorbala A.A., Akhondzadeh S., Tahmacebi-Pour N., et al. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol 2005, 97(2):281-284. 10.1016/j.jep.2004.11.004.
8. Berger F., Hensel A., Nieber K. Saffron extract and trans-crocetin inhibit glutamatergic synaptic transmission in rat cortical brain slices. Neuroscience 2011, 180:238-247. 10.1016/j.neuroscience.2011.02.037.
9. Agha-Hosseini M., Kashani L., Aleyaseen A., et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG 2008, 115(4):515-519. 10.1111/j.1471-0528.2007.01652.x.
10. Fukui H., Toyoshima K., Komaki R. Psychological and neuroendocrinological effects of odor of saffron (Crocus sativus). Phytomedicine 2011, 18(8-9):726-730. 10.1016/j.phymed.2010.11.013.
11. Shamsa A., Hosseinzadeh H., Molaei M., et al. Evaluation of Crocus sativus L. (saffron) on male erectile dysfunction: a pilot study. Phytomedicine 2009, 16(8):690-693. 10.1016/j.phymed.2009.03.008.
12. Modabbernia A., Sohrabi H., Nasehi A.A., et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology (Berl) 2012, 10.1007/s00213-012-2729-6.
13. Kashani L., Raisi F., Saroukhani S., et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol 2012, in press. http://dx.doi.org/10.1002/hup.2282.
14. Geromichalos G.D., Lamari F.N., Papandreou M.A., et al. Saffron as a source of novel acetylcholinesterase inhibitors: molecular docking and in vitro enzymatic studies. J Agric Food Chem 2012, 60(24):6131-6138. 10.1021/jf300589c.
15. Nam K.N., Park Y.M., Jung H.J., et al. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol 2010, 648(1-3):110-116. 10.1016/j.ejphar.2010.09.003.
16. Akhondzadeh S., Sabet M.S., Harirchian M.H., et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: a 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther 2010, 35(5):581-588. 10.1111/j.1365-2710.2009.01133.x.
17. Modaghegh M.H., Shahabian M., Esmaeili H.A., et al. Safety evaluation of saffron (Crocus sativus) tablets in healthy volunteers. Phytomedicine 2008, 15(12):1032-1037. 10.1016/j.phymed.2008.06.003.
18. Mansoori P., Akhondzadeh S., Raisi F., et al. A randomized, double-blind, placebo-controlled study of safety of the adjunctive saffron on sexual dysfunction induced by a selective serotonin reuptake inhibitor. Journal of Medicinal Plants 2011, 10(37):121-130.
19. Wuthrich B., Schmid-Grendelmeyer P., Lundberg M. Anaphylaxis to saffron. Allergy 1997, 52(4):476-477.
20. Akhondzadeh S., Naghavi H.R., Vazirian M., et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 2001, 26(5):363-367.
21. Aslanargun P., Cuvas O., Dikmen B., et al. Passiflora incarnata Linneaus as an anxiolytic before spinal anesthesia. J Anesth 2012, 26(1):39-44. 10.1007/s00540-011-1265-6.
22. Movafegh A., Alizadeh R., Hajimohamadi F., et al. Preoperative oral Passiflora incarnata reduces anxiety in ambulatory surgery patients: a double-blind, placebo-controlled study. Anesth Analg 2008, 106(6):1728-1732. 10.1213/ane.0b013e318172c3f9.
23. Appel K., Rose T., Fiebich B., et al. Modulation of the gamma-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res 2011, 25(6):838-843. 10.1002/ptr.3352.
24. Ngan A., Conduit R. A double-blind, placebo-controlled investigation of the effects of Passiflora incarnata (passionflower) herbal tea on subjective sleep quality. Phytother Res 2011, 25(8):1153-1159. 10.1002/ptr.3400.
25. Akhondzadeh S., Kashani L., Mobaseri M., et al. Passionflower in the treatment of opiates withdrawal: a double-blind randomized controlled trial. J Clin Pharm Ther 2001, 26(5):369-373.
26. Dhawan K., Dhawan S., Sharma A. Passiflora: a review update. J Ethnopharmacol 2004, 94(1):1-23. pii: S0378874104000856. 10.1016/j.jep.2004.02.023.
27. Fisher A.A., Purcell P., Le Couteur D.G. Toxicity of Passiflora incarnata L. J Toxicol Clin Toxicol 2000, 38(1):63-66.
28. Fernandez-San-Martin M.I., Masa-Font R., Palacios-Soler L., et al. Effectiveness of valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med 2010, 11(6):505-511. pii: S1389-9457(10)00100-0. 10.1016/j.sleep.2009.12.009.
29. Andreatini R., Sartori V.A., Seabra M.L., et al. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 2002, 16(7):650-654. 10.1002/ptr.1027.
30. Pakseresht S., Boostani H., Sayyah M. Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study. J Complement Integr Med 2011, 8(1). 10.2202/1553-3840.1465.
31. Taibi D.M., Landis C.A., Petry H., et al. A systematic review of valerian as a sleep aid: safe but not effective. Sleep Med Rev 2007, 11(3):209-230. 10.1016/j.smrv.2007.03.002.
32. Vassiliadis T., Anagnostis P., Patsiaoura K., et al. Valeriana hepatotoxicity. Sleep Med 2009, 10(8):935. pii: S1389-9457(08)00276-1. 10.1016/j.sleep.2008.09.009.
33. Yao M., Ritchie H.E., Brown-Woodman P.D. A developmental toxicity-screening test of valerian. J Ethnopharmacol 2007, 113(2):204-209. 10.1016/j.jep.2007.05.028.
34. Akhondzadeh S., Abbasi S.H. Herbal medicine in the treatment of Alzheimer's disease. Am J Alzheimers Dis Other Demen 2006, 21(2):113-118.
35. Akhondzadeh S., Noroozian M., Mohammadi M., et al. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 2003, 28(1):53-59.
36. Lachenmeier D.W., Uebelacker M. Risk assessment of thujone in foods and medicines containing sage and wormwood-evidence for a need of regulatory changes?. Regul Toxicol Pharmacol 2010, 58(3):437-443. pii: S0273-2300(10)00139-X. 10.1016/j.yrtph.2010.08.012.
37. Halicioglu O., Astarcioglu G., Yaprak I., et al. Toxicity of Salvia officinalis in a newborn and a child: an alarming report. Pediatr Neurol 2011, 45(4):259-260. pii: S0887-8994(11)00217-7. 10.1016/j.pediatrneurol.2011.05.012.